Current Report Filing (8-k)
September 02 2022 - 7:31AM
Edgar (US Regulatory)
0001270073
false
0001270073
2022-09-01
2022-09-01
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported): September 1, 2022
Intercept
Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware | |
001-35668 | |
22-3868459 |
(State or other jurisdiction | |
(Commission | |
(IRS Employer |
of incorporation) | |
File Number) | |
Identification No.) |
305 Madison Avenue, Morristown, NJ 07960
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including
area code: (646) 747-1000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ¨ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading
Symbol(s) |
Name of each exchange on which
registered |
Common Stock, par value $0.001 per share |
ICPT |
Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 1.01 Entry into a Material Definitive
Agreement.
On September 1, 2022, Intercept Pharmaceuticals, Inc. (the “Company”)
entered into privately-negotiated Exchange Agreements with a limited number of existing holders of its 3.50% Convertible Senior Secured
Notes due 2026 (the “2026 Notes”).
These noteholders are institutional “accredited investors”
(within the meaning of Rule 501(a)(1), (2), (3) or (7) promulgated under the Securities Act of 1933, as amended (the “Securities
Act”)) and/or “qualified institutional buyers” (as defined in Rule 144A under the Securities Act).
The parties agreed to exchange approximately $44.5 million aggregate
principal amount of the noteholders’ existing 2026 Notes for $22.7 million in cash and 1,653,130 shares of newly issued common stock,
par value $0.001 per share (equivalent to $29.9 million at the Company’s closing stock price of $18.06 on September 1, 2022), for
total consideration of $52.6 million.
This exchange is in addition to the Company’s previous exchange
of $327.9 million of 2026 Notes for cash and stock, which closed on August 25, 2022. Net of these exchanges, the principal balance of
the 2026 Notes has been reduced from $500.0 million to $127.6 million.
The stock being issued has not been, and will not be, registered under
the Securities Act, or any state securities laws, and may not be offered or sold in the United States absent registration or an applicable
exemption from (or in a transaction not subject to) registration requirements. This current report is not an offer to sell or a solicitation
of an offer to buy the Company’s common stock, or any other securities, and will not constitute an offer, solicitation, or sale
in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful.
The exchange is expected to close on or around September 6, 2022, subject
to customary closing conditions.
The foregoing description of the Exchange Agreements does not purport
to be complete and is qualified in its entirety by reference to the form of the Exchange Agreements, which is incorporated by reference
from the exhibit list below.
This current report contains forward-looking statements (“FLS”),
including regarding closing of the transaction, and timing thereof. Important factors could cause actual results to differ materially
from the FLS, including the Company’s and noteholders’ satisfaction of contractual terms, including representations and warranties
and closing conditions.
Item 3.02 Unregistered Sales of Equity
Securities.
As described above, the Company expects to issue 1,653,130 shares of
common stock to the noteholders as part of the consideration for the exchange of 2026 Notes. The issuances of common stock will be made
in private placements in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act. The Company is
relying on this exemption from registration based in part on representations made by the noteholders in the Exchange Agreements. The information
set forth in Item 1.01 above is incorporated by reference into this Item 3.02.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
* Incorporated by reference to the previously filed Exhibit 10.1 to
the Form 8-K filed on August 19, 2022, File No. 001-35668. This current report’s Exhibit 10.1 is substantially identical to
the previously filed exhibit in all material respects except that the execution date has been changed from August 18 to September 1, the
closing date has been changed from August 25 to September 6, and the termination date has been changed from ten business days to September
16.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
INTERCEPT PHARMACEUTICALS, INC. |
|
|
|
By: |
/s/ Andrew Saik |
|
Name: |
Andrew Saik |
|
Title: |
Chief Financial Officer |
Date: September 2, 2022
Intercept Pharmaceuticals (NASDAQ:ICPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Intercept Pharmaceuticals (NASDAQ:ICPT)
Historical Stock Chart
From Apr 2023 to Apr 2024